Lantern Pharma (LTRN) Reports Q3 2025 Results | LP-184 Trial Hits All Endpoints

Biotech investors and oncology researchers: Lantern Pharma (NASDAQ: LTRN) has announced its Q3 2025 financial results, highlighting strong clinical and regulatory progress across its oncology programs.

📌 Key Highlights:

LP-184 Phase 1 trial achieved all primary endpoints

Completed FDA Type C meeting for pediatric CNS cancer trial (Starlight Therapeutics)

LP-300 Phase 2 Harmonic Trial preliminary data presented in Japan

Further updates to be shared in a December webinar

Cash & equivalents: $12.4M as of Sept 30, 2025

R&D spend: $2.4M for the quarter

Lantern continues advancing innovative cancer therapies through AI-driven drug development and precision oncology.

#LanternPharma #LTRN #BiotechStocks #OncologyResearch #CancerTherapy #ClinicalTrials #LP184 #LP300 #PrecisionMedicine #FDAApproval #PharmaInnovation #InvestorNews #StarlightTherapeutics #NewsOut #JaneKing